About Us

Veritomyx, Inc. mass spectral analysis software applies advanced signal-processing and identification algorithms to reveal previously hidden data and accelerate correct proteomic and metabolomic biomolecular identifications. Inaccurate results misdirect research while wasting valuable time and resources. Veritomyx software minimizes these problems by extracting important hidden information with statistical confidence from new and existing spectra, producing more effective research and development.

Veritomyx is a subsidiary of Target Discovery, Inc., which discovers and utilizes protein isoforms to improve clinical diagnosis and management of disease. From these efforts, Target Discovery has developed advanced spectral-analysis tools that Veritomyx makes commercially available to life-science researchers worldwide.

Focus on Accuracy and Precision

Inaccurate biomolecular identifications lead to misdirected research, often at great cost in R&D investments and in medical innovations delayed or never achieved. Veritomyx’ advanced algorithms extract critical insights missed or misidentified by other leading mass spectral analysis methods. PeakInvestigator™ software delivers unique peak detection and precise deconvolution capabilities to reveal hidden overlapped peaks that current software misses. We provide 3-4x increases in the effective resolution of your existing mass analyzer, delivering up to 10-fold improvements in mass and abundance precision when deconvolving previously hidden overlapped peaks. This precision accelerates research to validated, accurate identifications.


Jeff Peterson headshot

Jeffrey N. Peterson, CEO, is the CEO of Target Discovery, the parent company of Veritomyx. Mr. Peterson also serves as Chairman of Pressure Biosciences (PBIO) and of Imaging3 (IGNG). His broad executive leadership experience included a career in Abbott Laboratories, as CEO & GM of Abbott South Africa, and in pivotal roles in Abbott Diagnostics. He was previously CEO of SPO&A international business development consulting, and had a career rising through General Electric’s Engineered Materials and Plastics businesses. Mr. Peterson holds BSChemE and MSChemE degrees from MIT, and he has coauthored six issued patents and multiple scientific articles. Mr. Peterson serves on the Advisory Board for the California Technology Council and served 12 years on the Board of BayBio (CA Life Sciences Association). Mr. Peterson has been an active leader in the Coalition for 21st Century Medicine and in BIO's Personalized Medicine & Diagnostics Group. He is Chair Emeritus of the BayBio Institute, served on the University of Texas MD Anderson Cancer Center’s Board of Advisors for the Center for Professional Development and Entrepreneurship, and continues to advise rising entrepreneurs.

Mark Duncan headshot

Dr. Mark Duncan, Chief Scientific Officer, and CSO at Target Discovery, has extensive experience in mass spectrometry, clinical diagnostics and analytical chemistry. Dr. Duncan was a Postgraduate Scholar at the Garvan Institute of Medical Research, Sydney, Australia and thereafter, a Fogerty Fellow, National Institute of Neurological Disorders & Stroke, National Institutes of Health (NIH), Bethesda, MD. He has held appointments as a Professor (Medicine) at Universities in Australia, the USA and Saudi Arabia and has established and directed proteomics/MS centers at three international institutions. He has also held senior appointments in industry and is a co-developer of Veristrat®, a blood-based diagnostic used in the management of patients with non-small cell lung cancer marketed by Biodesix, Inc., Boulder, Colorado. He has published over 150 publications and has 8 issued patents. Dr. Duncan is co-editor, Special Features, Journal of Mass Spectrometry, he is on the editorial board, Journal of Clinical Mass Spectrometry and he is a member of the Committee on Quantitative Measurement of Proteins & Peptides by MS (C64), Clinical & Laboratory Standards Institute.

Adam Tenderholt headshot

Dr. Adam Tenderholt, Director of Technology and Veritomyx Program, holds a Ph.D. in Physical Chemistry (Stanford University) and dual B.A. degrees in Chemistry and Integrated Science (Northwestern University). He was a postdoctoral scholar at the University of Washington where he studied proton-coupled electron transfer mechanisms using a variety of experimental and computational approaches. As a graduate student, he developed software for the processing and analysis of both experimental data (PySpline) and quantum chemical calculations (cclib and QMForge) and was responsible for the design and maintenance of a high-performance computational cluster. Dr. Tenderholt has coauthored numerous publications in high-profile peer-reviewed journals. His Journal of Computational Chemistry publication describing the cclib platform for package‐independent computational chemistry algorithms has been cited over 2,000 times. Dr. Tenderholt is a member of the American Chemical Society and the American Society for Mass Spectrometry.